Enterprise Value
-12.54M
Cash
73.02M
Avg Qtr Burn
-20.1M
Short % of Float
0.31%
Insider Ownership
1.32%
Institutional Own.
27.52%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ABI-H3733 Details Liver disease, Hepatitis B, Liver infection | Phase 1b Data readout | |
ABI-4334 Details Liver infection, Liver disease, Hepatitis B | Phase 1a Interim update | |
ABI-H2158 Details Liver infection, Liver disease, Hepatitis B | Failed Discontinued | |
Vebicorvir (VBR, ABI-H0731) Details Liver infection, Chronic liver disease, Hepatitis B | Failed Discontinued |